Krämer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K, Mileshkin L, Moch H, Oien K, Olivier TJAO. Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up. 2023;34(3):228–46.

Hainsworth JD, Greco FA. Adenocarcinoma of unknown primary site, in holland-Frei cancer medicine. 6th ed. BC Decker; 2003. edition.

Google Scholar 

Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara NJJCO. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. 2019;37(7):570–9.

Pentheroudakis G, Golfinopoulos V, Pavlidis NJE. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. 2007;43(14):2026–36.

Lee MS, Sanoff HKJB. Cancer Unkn Prim. 2020;371.

Beauchamp K, Moran B, O’Brien T, Brennan D, Crown J, Sheahan K, Cotter MBJC, Reviews M. Carcinoma of unknown primary (CUP): an update for histopathologists. 2023;42(4):1189–200.

von der Müller von der Grün J, Tahtali A, Ghanaati S, Rödel C, Balermpas PJRO. Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site-current status and challenges. 2017;12(1):82.

Rassy E, Abou-Jaoude R, Boussios S, Assi T, Kattan J, Khaled H, Pavlidis NJJOTENCI. Sarcoma of unknown primary: myth or reality? 2022;34(1):27.

Pisacane A, Cascardi E, Berrino E, Polidori A, Sarotto I, Casorzo L, Panero M, Boccaccio C, Verginelli F, Benvenuti SJVA. Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs). 2023;482(3):463–75.

Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol. 2020;96:8–33.

Article  PubMed  Google Scholar 

Spurgeon L, Mitchell C, Cook N, Conway AM. Cancer of unknown primary: the hunt for its elusive tissue-of-origin—is it time to call off the search? Br J Cancer. 2025;.

Möhrmann L, Werner M, Oleś M, Mock A, Uhrig S, Jahn A, Kreutzfeldt S, Fröhlich M, Hutter B, Paramasivam NJNC. Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. 2022;13(1):4485.

Krämer A, Bochtler T, Pauli C, Shiu K‑K, Cook N, de Menezes JJ, Pazo-Cid RA, Losa F, Robbrecht DG, Tomášek JJTL. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. 2024;404(10452):527–39.

Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MCJTLO. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. 2016;17(10):1386–95.

Liu X, Zhang X, Jiang S, Mo M, Wang Q, Wang Y, Zhou L, Hu S, Yang H, Hou YJTLO. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. 2024;25(8):1092–102.

Lorkowski SW, Dermawan JK, Rubin BPJVA. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review. 2024;484(2):369–75.